EP3341389B1 - Inhibiteurs peptidiques de translocation de la télomérase et leurs utilisations thérapeutiques - Google Patents

Inhibiteurs peptidiques de translocation de la télomérase et leurs utilisations thérapeutiques Download PDF

Info

Publication number
EP3341389B1
EP3341389B1 EP16762938.5A EP16762938A EP3341389B1 EP 3341389 B1 EP3341389 B1 EP 3341389B1 EP 16762938 A EP16762938 A EP 16762938A EP 3341389 B1 EP3341389 B1 EP 3341389B1
Authority
EP
European Patent Office
Prior art keywords
peptide
seq
tert
inhibitor
nuclear translocation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16762938.5A
Other languages
German (de)
English (en)
Other versions
EP3341389A1 (fr
Inventor
Johnathan D. EBBEN
Andreas M. BEYER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical College of Wisconsin
Original Assignee
Medical College of Wisconsin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College of Wisconsin filed Critical Medical College of Wisconsin
Publication of EP3341389A1 publication Critical patent/EP3341389A1/fr
Application granted granted Critical
Publication of EP3341389B1 publication Critical patent/EP3341389B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • telomere reactivation of the telomerase enzyme in certain cell types may also be an important event in oncogenic transformation, given the role of telomerase in cellular immortalization and proliferation.
  • the mechanisms that underlie the beneficial effects of telomerase reactivation in the prevention and amelioration of cardiac and vascular diseases have to this point been unclear.
  • compositions and therapeutic and prophylactic methods that overcome the deficiencies of standard protocols and provide new treatment paradigms for vascular diseases while mitigating adverse or off-target side effects of chemotherapeutic cancer treatments.
  • the present invention overcomes the aforementioned drawbacks by providing compositions and methods as described herein.
  • an isolated peptide comprising an amino acid sequence as set forth by: by SEQ ID NO:2 or SEQ ID NO:4, the isolated peptide being capable of preventing TERT nuclear translocation.
  • the isolated peptide can have the sequence forth as SEQ ID NO:2.
  • the peptide can be blood brain barrier (BBB)-permeant.
  • an isolated polynucleotide comprising a nucleic acid sequence encoding a peptide comprising an isolated peptide as provided herein.
  • a peptide inhibitor of TERT nuclear translocation comprising SEQ ID NO:2 or SEQ ID NO:4 for use in a method of preventing nuclear translocation of a telomerase enzyme in a human cell, the method comprising contacting the human cell to the inhibitor of TERT nuclear translocation.
  • the administration can be parenteral administration.
  • an in vitro method of preventing nuclear translocation of a telomerase enzyme in a human cell the method comprising contacting the human cell to an inhibitor of TERT nuclear translocation comprising SEQ ID NO: 2 or SEQ ID NO:4.
  • a peptide inhibitor of TERT nuclear translocation comprising SEQ ID NO: 2 or SEQ ID NO:4 for use in a method of reducing adverse cardiac effects in a subject, the method comprising administering a therapeutically effective amount of an inhibitor of TERT nuclear translocation to a subject, wherein administering the synthetic peptide reduces occurrence of adverse cardiac effects in the subject.
  • the adverse cardiac effects can be cardiotoxicity associated with administration of a chemotherapeutic agent to the subject.
  • the subject will receive or is receiving a chemotherapeutic agent.
  • the inhibitor of TERT nuclear translocation can be a peptide.
  • the peptide can have a sequence selected from the group consisting of SEQ ID NO:2, and SEQ ID NO:4.
  • the administration can be parenteral administration.
  • an isolated peptide comprising SEQ ID NO:2 or SEQ ID NO:4 for use in a method of treating a hyperproliferative disease in a subject, the method comprising administering to the subject a therapeutically effective amount of an isolated peptide into the subject; the isolated peptide being capable of preventing TERT nuclear translocation, thereby treating the hyperproliferative disease.
  • the hyperproliferative disease can be cancer.
  • the peptide can be PEGylated.
  • the PEGylated peptide can comprise the sequence set forth in SEQ ID NO:4.
  • a peptide inhibitor of TERT nuclear translocation comprising SEQ ID NO:2 or SEQ ID NO:4 for use in a method of reducing oxidative stress, the method comprising administering to a subject an effective amount of the inhibitor of TERT nuclear translocation
  • TERT dysregulation plays an important role in many vascular disease phenotypes, including vascular dysfunction associated with coronary artery disease (CAD), and that TERT expression confers cardioprotection in the adult mouse heart after MI
  • CAD coronary artery disease
  • TERT expression confers cardioprotection in the adult mouse heart after MI
  • off-target toxicities including vascular and cardiac damage.
  • compositions and methods provided herein are based at least in part on the discovery that TERT accumulation in the nucleus is significantly attenuated following peptide inhibitor administration. It was further discovered that mitochondrial-associated telomerase, and not nuclear telomerase, is the cause of cardiovascular protection associated with telomerase activity, while NLS peptide inhibitors protect isolated human vessels from damage in response to stress and may decrease migration of lung tumor cells. Inhibition of nuclear transport of TERT, the catalytic subunit of telomerase, increases cytoplasmic (including mitochondrial) telomerase localization and activity.
  • compositions and methods that harness the benefits of telomerase overexpression in cardiac and vascular disease without increasing cancer risk, and also provide improved means of inhibiting nuclear telomerase in cancer in a manner that is less toxic.
  • NLS peptide inhibitor compositions provided herein can be used in combination with traditional and targeted cancer therapies to minimize toxicity to the vasculature and heart.
  • the present invention provides a in a first aspect, provided herein is an isolated peptide comprising an amino acid sequence as set forth by SEQ ID NO:2 or SEQ ID NO:4, the isolated peptide being capable of preventing TERT nuclear translocation.
  • the synthetic peptide can effectively compete with endogenous localization signals for modification by kinases within the cell.
  • the NLS- containing peptide compositions and MLS-containing peptide compositions described herein are believed to be the first telomerase inhibitors that specifically inhibit only the nuclear and mitochondrial functions of TERT, respectively.
  • the isolated peptide provided is capable of preventing TERT nuclear translocation.
  • the peptides described herein are believed to be the first telomerase inhibitors that specifically inhibit only the nuclear function of TERT. By mimicking TERT's nuclear localization signal, the inhibitory peptide blocks or attenuates the ability of endogenous telomerase to move from the cytosol to the nucleus.
  • the synthetic peptides of the invention are blood-brain barrier (BBB) permeant peptides.
  • BBB permeant peptides are characterized by the ability of the peptide to penetrate the blood brain barrier formed by brain capillary endothelial cells.
  • blood-brain barrier or “BBB” refers to that obstacle to biological transport of drugs, ions, peptides, proteins and toxins that is formed by the membrane properties, structure and tight junctions of brain capillary endothelial cells.
  • amino acid is broadly defined to include naturally occurring amino acids as well as non-naturally occurring amino acids, including amino acid analogs and derivatives, such as molecules containing an amino acid moiety.
  • amino acid therefore embraces, for example, naturally occurring proteogenic L-amino acids; D-amino acids; chemically modified amino acids such as amino acid analogs and derivatives; naturally occurring non-proteogenic amino acids such as norleucine, ⁇ -alanine, ornithine, etc.; and chemically synthesized compounds having properties known in the art to be characteristic of amino acids, including non-native ⁇ -amino acids, those containing non-natural side chains, and D-amino acids as well as inverso and retro-inverso peptide sequences.
  • the isolated peptide provided is one comprising an amino acid sequence as set forth by SEQ ID NO: 2 or SEQ ID NO: 4, the isolated peptide being capable of preventing TERT nuclear translocation.
  • the synthetic peptide is a phosphomimetic peptide, meaning the peptide comprises a "phosphomimetic" amino acid, e.g., an aspartic acid (D), or a glutamic acid (E), in place of a naturally-occurring phosphorylated amino acid.
  • a phosphomimetic amino acid e.g., an aspartic acid (D), or a glutamic acid (E)
  • D aspartic acid
  • E glutamic acid
  • proteins are commonly modified at serine, tyrosine, and threonine amino acids by adding a phosphate group.
  • Phosphomimetic (also called “phospho-mimicking") peptides of the invention can be obtained through substitution of a phosphorylated residue (e.g., a serine residue) with a negatively charged amino acid residue (to mimic the negative charge of the phosphate group), such as aspartic acid (D) or glutamic acid (E). Aspartic acid and glutamic acid are chemically similar to phosphorylated serine ("phospho-serine"). When, for example, an aspartic acid replaces a serine, it is a phosphomimetic of phospho-serine and the resulting peptide is always in its phosphorylated form and, thus, constitutively active.
  • a phosphorylated residue e.g., a serine residue
  • a negatively charged amino acid residue to mimic the negative charge of the phosphate group
  • Aspartic acid and glutamic acid are chemically similar to phosphorylated serine (“phospho-serine").
  • phospho-serine When, for
  • a phosphomimetic peptide as provided herein has the amino acid sequence set forth as SEQ ID NO:2 (RRRGGEASRSLPLPKRPRR).
  • This peptide referred to as nucXTERT-E in the Examples section, comprises a glutamic acid (E) in place of the serine residue found at position 6 of SEQ ID NO: 1)(RRRGGSASRSLPLPKRPRR).
  • a phosphomimetic peptide that has the amino acid sequence set forth as SEQ ID NO:7 (RRRGGDASRSLPLPKRPRR), where the peptide comprises an aspartic acid (D) in place of the serine residue found at position 6 of SEQ ID NO:1.
  • the serine at position 6 of SEQ ID NO: 1 corresponds to position 227 of the amino acid sequence encoding telomerase enzyme (OMIM ID 187270; GenBank: AAD30037.1). Phosphorylation of the serine at position 227 of the wild-type telomerase sequence enables nuclear import of telomerase.
  • phosphomimetic peptides as described herein are provided for use as a medicament or for use in conjunction with one or more therapeutics. According to more specific embodiments, such phosphomimetic peptides are provided to reduce or mitigate oxidative stress, or for use in the treatment of cancer or in the treatment of cardiac and/or vascular disease, including peripheral vascular diseases.
  • Peripheral vascular diseases include, without limitation, hypertrophy, diabetic retinopathy, diseases of the adipose vessels and other vascular beds.
  • a synthetic peptide provided which is phospho-deficient, where an amino acid substitution removes a phosphorylated amino acid from the resulting peptide or polypeptide.
  • a phospho-deficient peptide can comprise a substitution of a non-phosphorylatable amino acid residue such as alanine in place of a phosphorylated amino acid in the peptide sequence set forth in SEQ ID NO:1.
  • a phosphodeficient synthetic peptide has the amino acid sequence set forth as SEQ ID NO:3 (RRRGGAASRSLPLPKRPRR).
  • nucXTERT-A comprises an alanine (A) in place of the serine residue found at position 6 of SEQ ID NO:1)(RRRGGSASRSLPLPKRPRR).
  • A alanine
  • nucXTERT/nucXTERT-W corresponds to position 227 of the amino acid sequence encoding telomerase enzyme (OMIM ID 187270; GenBank: AAD30037.1).
  • the synthetic peptides provided herein comprise a poly(ethylene glycol) moiety.
  • Such peptides are referred to herein as PEGylated peptides.
  • PEGylated refers to the covalent attachment of poly(ethylene glycol) (“PEG”) residue to a peptide as provided herein by PEGylation.
  • peptides are PEGylated at the N- and/or C-terminus to increase biostability and cell permeability.
  • a synthetic peptide of the invention can have a PEGylated amino acid sequence as set forth in SEQ ID NO:4 (Ac-CGGRRRGGEASRSLPLPKRPRR-pegl2-amide, where "Ac” refers to acetylation, which can increase peptide stability by preventing N-terminal degradation).
  • Ac refers to acetylation, which can increase peptide stability by preventing N-terminal degradation.
  • the acetylation of a peptide's N-terminal cysteine forms the derivative N-acetyl-L-cysteine.
  • PEGylation means a covalent linkage of a poly(ethylene glycol) residue at the N-terminus of the polypeptide and/or an internal lysine residue.
  • PEGylation of proteins is widely known in the state of the art and is reviewed by, for example, Veronese, F. M., Biomaterials 22 (2001) 405-417 .
  • PEG can be linked using different functional groups and polyethylene glycols with different molecular weight, linear and branched and forked PEGs as well as different linking groups (see also Francis, G. E., et al., Int. J. Hematol. 68 (1998) 1-18 ; Delgado, C., et al., Crit. Rev.
  • PEG polyethylene glycol
  • poly(ethylene glycol) refers to any water soluble poly(ethylene oxide), and includes molecules comprising the structure --(CH 2 CH 2 O) n -- where n is an integer from 2 to about 800.
  • a commonly used PEG is end-capped PEG, wherein one end of the PEG is capped with a relatively inactive group such as an alkoxy while the other end is a hydroxyl group that may be further modified.
  • An often used capping group is methoxy, and the corresponding end-capped PEG is often denoted mPEG.
  • the notion PEG is often used instead of mPEG.
  • PEG polymer molecules used in a PEGylation reaction have a molecular weight of about 10 kDa to 40 kDa (by "molecular weight” as used herein there is to be understood the mean molecular weight of the PEG because PEG as a polymeric compound is not obtained with a defined molecular weight but in fact has a molecular weight distribution; the term "about” indicates that in said PEG preparations, some molecules will weigh more and some less than the indicated molecular weight, i.e., the term about refers to a molecular weight distribution in which 95% of the PEG molecules have a molecular weight within +/-10% of the indicated molecular weight).
  • PEG is a well-known polymer with good solubility in many aqueous and organic solvents, which exhibits low toxicity, lack of immunogenicity, and is clear, colorless, odorless, and stable. For these reasons and others, PEG has been selected as the preferred polymer for attachment, but it has been employed solely for purposes of illustration and not limitation.
  • Similar products may be obtained with other water-soluble polymers, including without limitation; polyvinyl alcohol, other poly(alkylene oxides) such as poly(propylene glycol) and the like, poly(oxyethylated polyols) such as poly(oxyethylated glycerol) and the like, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl purrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride, and polyaminoacids.
  • polyvinyl alcohol other poly(alkylene oxides) such as poly(propylene glycol) and the like
  • poly(oxyethylated polyols) such as poly(oxyethylated glycerol) and the like
  • carboxymethylcellulose carboxymethylcellulose
  • dextran polyvinyl alcohol
  • polyvinyl purrolidone poly-1,3-dioxolane
  • PEG derivatives are both commercially available and suitable for use in the preparation of the PEG-conjugated peptides of the invention.
  • Suitable PEG derivatives are activated PEG molecules with an average molecular weight of from about 5 to about 40 kDa, in one embodiment from about 20 to about 40 kDa, preferably about 30 kDa to about 35 kDa.
  • the PEG derivative is in one embodiment a linear or a branched PEG.
  • a wide variety of PEG derivatives suitable for use in the preparation of PEGylated peptides as provided herein can be obtained from Shearwater Polymers (Huntsville, Ala., U.S.A.; nektar.com on the World Wide Web).
  • a synthetic peptide provided herein can comprise a myristoyl group by myristoylation.
  • myristoylated and myristoylation refer to a lipidation modification in which a myristoyl group, derived from myristic acid, is covalently attached by an amide bond to the alpha-amino group of an N-terminal glycine residue.
  • the myristoyl group is a 14-carbon saturated fatty acid (C14), which gives the protein sufficient hydrophobicity and affinity for membranes, but not enough to permanently anchor the protein in the membrane.
  • N-myristoylation therefore acts as a conformational localization switch, in which protein conformational changes influence affinity of a peptide or polypeptide for membrane attachment. Because of this conditional localization, signal proteins that selectively localize to membrane, such as Src-family kinases, are N-myristoylated.
  • peptide modifications appropriate for use with the peptides provided herein include, without limitation, glycosylations, acetylations, phosphorylations, as well as the addition of peptide linkers such as a cysteine linker or spacer.
  • Peptide modifications can occur at the N-terminal and/or C-terminal ends of a peptide.
  • the amino and/or carboxy termini of a peptide can be modified produce other compounds of the invention.
  • Amino terminus modifications include methylation (i.e.,-NHCH 3 or-N (CH 3 ) 2 ), acetylation (e.
  • acetic acid or a halogenated derivative thereof such as a-chloroacetic acid, a-bromoacetic acid, or a-iodoacetic acid
  • adding a benzyloxycarbonyl (Cbz) group or blocking the amino terminus with any blocking group containing a carboxylate functionality defined by RCOO-or sulfonyl functionality defined by R--SO 2 -, where R is selected from the group consisting of alkyl, aryl, heteroaryl, alkyl aryl, and the like, and similar groups.
  • the N-terminus is acetylated.
  • an N- terminal glycine is acetylated to yield N-acetylglycine (AcG).
  • spacers or linkers such as cysteine (Cys) linkers are used to attach various moieties (e.g., radiolabel-binding moiety, chelating moiety, spacer moiety) or cargo molecules (e.g., a nucleic acid, peptide nucleic acid (PNA), phosphorodiamidate morpholino oligonucleotide (PMO), locked nucleic acid (LNA), antisense oligonucleotide, short interfering RNA (siRNA), peptide, cyclic peptide, protein, antibody, or drug) to a peptide provided herein.
  • moieties e.g., radiolabel-binding moiety, chelating moiety, spacer moiety
  • cargo molecules e.g., a nucleic acid, peptide nucleic acid (PNA), phosphorodiamidate morpholino oligonucleotide (PMO), locked nucleic acid (LNA), antisense
  • peptides can be covalently linked to a radiolabel-binding moiety that is stably complexed with a radioisotope such as, for example, technetium-99m.
  • linker sequences allow chemical linkage of the peptide to a cargo molecule.
  • linker sequences act as a spacer to separate the peptide from the cargo.
  • cysteine residues permits formation of a disulphide, thioether or thiol-maleimide linkage.
  • amino acid spacers and cargo molecules are chemically linked by covalent bonds.
  • a synthetic peptide that is an inhibitor of TERT mitochondrial localization.
  • the inhibitory peptide blocks or attenuates the ability of endogenous telomerase to move from the cytosol into mitochondria.
  • the synthetic peptide that inhibits TERT mitochondrial localization is peptide having the amino acid sequence as set forth in SEQ ID NO:5 (MPRAPRCRAVRSLLRSHYRE). This peptide is referred to as mitoXTERT in the Examples section.
  • the peptides of the present invention can be biochemically synthesized such as by using standard solid phase techniques. These methods include exclusive solid phase synthesis, partial solid phase synthesis methods, fragment condensation, classical solution synthesis. These methods are preferably used when the peptide is relatively short (i.e., 10 kDa) and/or when it cannot be produced by recombinant techniques (i.e., not encoded by a nucleic acid sequence) and therefore involves different chemistry.
  • Synthetic peptides can be purified by preparative high performance liquid chromatography [ Creighton T. (1983) Proteins, structures and molecular principles. WH Freeman and Co. N.Y .] and the composition of which can be confirmed via amino acid sequencing.
  • Recombinant techniques may also be used to generate the peptides and/or polypeptides of the present invention. These techniques may be preferred when the peptide is linked to a heterologous protein (i.e. a fusion protein) since recombinant techniques are better suited for generation of relatively long polypeptides (e.g., longer than 20 amino acids) and large amounts thereof.
  • a heterologous protein i.e. a fusion protein
  • Such recombinant techniques are described by Bitter et al., (1987) Methods in Enzymol. 153:516-544 , Studier et al. (1990) Methods in Enzymol. 185:60-89 , Brisson et al. (1984) Nature 310:511-514 , Takamatsu et al.
  • a polynucleotide encoding the nuclear targeting peptide of the present invention is ligated into a nucleic acid expression vector, which comprises the polynucleotide sequence under the transcriptional control of a cis-regulatory sequence (e.g., promoter sequence) suitable for directing constitutive, tissue specific or inducible transcription of the polypeptides of the present invention in the host cells.
  • a cis-regulatory sequence e.g., promoter sequence
  • the expression construct of the present invention can also include sequences engineered to optimize stability, production, purification, yield or activity of the expressed peptide.
  • peptides and/or polypeptides of the present invention can be purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing, and differential solubilization.
  • standard protein purification techniques such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing, and differential solubilization.
  • the expressed coding sequence can be engineered to encode the polypeptide of the present invention and fused cleavable moiety.
  • a fusion protein can be designed so that the polypeptide can be readily isolated by affinity chromatography; e.g., by immobilization on a column specific for the cleavable moiety.
  • the polypeptide can be released from the chromatographic column by treatment with an appropriate enzyme or agent that specifically cleaves the fusion protein at this site (e.g., see Booth et al., Immunol. Lett. 19:65-70 (1988 ); and Gardella et al., J. Biol. Chem. 265:15854-15859 (1990 )).
  • the peptides and/or polypeptides of the present invention are preferably retrieved in "substantially pure” form.
  • the phrase “substantially pure” refers to a purity that allows for the effective use of the protein in the applications described herein.
  • isolated is meant material that is substantially or essentially free from components that normally accompany it in its native state.
  • an "isolated peptide” or an “isolated polypeptide” and the like, as used herein, includes the in vitro isolation and/or purification of a peptide or polypeptide molecule from its natural cellular environment, and from association with other components of the cell; i.e., it is not significantly associated with in vivo substances.
  • isolated peptides of the present invention for use in therapeutic methods.
  • the isolated peptide is provided for use in a method for reducing cardiotoxicity associated with cancer treatment (e.g., treatment with a chemotherapeutic agent), where the method comprises or consists essentially of administering an inhibitor of TERT nuclear translocation to a subject prior to or during administration of a chemotherapeutic agent.
  • the isolated peptide of the present invention is for use in a method where it is administered in conjunction with, sequentially or simultaneously, one or more chemotherapeutic agents to reduce the cardiac and vascular toxicities associated with such chemotherapeutic agents.
  • Chemotherapeutic agents associated with cardiac and vascular toxicities include, without limitation, those that inhibit telomerase, as well as doxorubicin and tyrosine kinase inhibitors.
  • Anti-cancer drugs that do not directly target TERT may generally inhibit the enzyme, resulting in off-target effects.
  • Administration of the inhibitor of TERT nuclear localization reduces cardiac and vascular toxicities that are otherwise dose-limiting.
  • telomerase activity is important for activation of cellular and tumor autophagy, which is a key chemotherapy resistance mechanism that renders many tumors less sensitive to chemotherapy. Without being bound by any particular mechanism or mode of action, it is believed that NLS peptide inhibitors and other inhibitors of TERT nuclear localization preserve mitochondrial TERT function while reducing or abolishing nuclear function of telomerase. As described in the Examples, the nuclear function of telomerase is important for cell transformation and tumorigenesis. Accordingly, administration of inhibitors of TERT nuclear localization to a subject receiving chemotherapy may increase the efficacy of the chemotherapeutics while protecting cardiac and vascular tissue from chemotherapy associated toxicity.
  • an isolated peptide of the present invention for use in a method for mitigating oxidative stress and metabolic effects associated with oxidative stress, where the method comprises or consists essentially of administering to a subject a therapeutically effective amount of a peptide of the present inventiono, whereby administration of the peptide boosts mitochondrial function.
  • the method comprises or consists essentially of administering to a subject a therapeutically effective amount of a peptide of the present inventiono, whereby administration of the peptide boosts mitochondrial function.
  • the peptides and their derivatives described herein may have utility in the treatment and amelioration of diseases with a significant oxidative stress component, including Parkinson's disease, Amytrophic Lateral Sclerosis (ALS), Alzheimer's disease, and other neurodegenerative conditions.
  • diseases with a significant oxidative stress component including Parkinson's disease, Amytrophic Lateral Sclerosis (ALS), Alzheimer's disease, and other neurodegenerative conditions.
  • ALS Amytrophic Lateral Sclerosis
  • Alzheimer's disease and other neurodegenerative conditions.
  • a peptide of the present invention for use in a method for reducing or ameliorating the negative vasoconstrictive effects associated with administration of Angiotensin II, where the method comprises or consists essentially of administering a peptide that inhibits TERT nuclear localization provided herein to a subject prior to, during, or following administration of Angiotensin II.
  • a peptide that inhibits TERT nuclear localization provided herein to a subject prior to, during, or following administration of Angiotensin II.
  • coronary and adipose vessels are less susceptible to the vasoconstrictive properties of Angiotensin II in the presence of the NLS peptide inhibitors described herein.
  • ANG II is elevated in many different pathologies, including some hypertensive states.
  • the peptide inhibitors and their derivatives described herein may be useful in the treatment of chronic and acute hypertension.
  • a peptide of the present invention for use in a method for reducing adverse or off-target effects of tyrosine kinase inhibitor (TKI) therapy in a subject receiving TKI therapy.
  • TKI tyrosine kinase inhibitor
  • some malignancies such as chronic myeloid leukemia, persistent tyrosine kinase inhibitor therapy maintains long remissions.
  • the TKIs have vascular side effects as patients continue to live longer.
  • TKI therapy ultimately fails over the course of many years, possibly because tumor cells are able to evade destruction by TKI therapy by inducing autophagy.
  • the method for reducing adverse or off-target effects of TKI comprises or consists essentially of administering an inhibitor of TERT nuclear localization to a subject in need thereof, whereby administration prevents, treats, or ameliorates off-target effects of TKIs on the vasculature.
  • a peptide of the present invention for use in a method of treating or preventing tumor metastasis. Also provided is a peptide of the present invention for use in a method for decreasing or inhibiting tumor cell migration.
  • the methods comprise or consist essentially of administering an inhibitor of TERT nuclear localization to a subject in need thereof, whereby administration prevents, treats, or ameliorates off-target effects of TKIs on the vasculature.
  • peptide of the present invention for use in a method of treating a cardiac disorder.
  • Administration of an inhibitor of TERT nuclear localization is effective to treat or prevent cardiac conditions or disorders including, without limitation, coronary artery disease, hypertension, and myocardial infarct.
  • a peptide of the present invention for use in a method of preventing or treating a cardiac disorder or condition, where the method comprises or consists essentially of administering the peptide to a subject predisposed exertion-related myocardial infarction, to a subject predisposed to the cardiac disorder as a result of impaired flow-mediated vascular dilation following myocardial infarction, to a subject having coronary artery disease (CAD), to a subject having normal cardiac vessels to present onset of the cardiac disorder or condition.
  • the method further comprises treating a subject following myocardial infarction (MI).
  • a peptide of the present invention for use in a method of preventing or treating endothelial dysfunction, where the method comprises or consist essentially of administering to a subject a therapeutically effective amount of an inhibitor of TERT nuclear localization.
  • Endothelial dysfunction is characterized by a loss of barrier function and an infiltration of cellular material into the vascular wall and loss of physiological vascular tone.
  • references to "treating endothelial dysfunction" are to be considered as references to improvement of endothelial function in treatment of disorders which are related to endothelial dysfunction.
  • Such disorders include both macrovascular disorders (relating to the large blood vessels) such as transient ischemic attack, stroke, angina, myocardial infarction, cardiac failure, and peripheral vascular disease, as well as microvascular disorders (relating to the small blood vessels) such as diabetic retinopathy (non-proliferative, proliferative, macular oedema), microalbuminuria, macroalbuminuria, end stage renal disease, erectile dysfunction, autonomic neuropathy, peripheral neuropathy, osteomyelitis and lower limb ischemia.
  • Administration of an inhibitor of TERT nuclear localization can improve endothelial function in the subject and, in some cases, treat angina induced by vasospasm of damaged vessels.
  • diseases and conditions for which the peptide of the present invention is particularly useful include those associated with endothelial dysfunction.
  • diseases and conditions include, without limitation, diabetes, dyslipidemia, hypertension, myocardial infarction, cardiovascular disease, coronary artery disease (CAD), microvessel disease, ischemic disease, peripheral artery disease, angina induced by vasospasm (e.g., Prinzmetal's angina), pre-eclampsia, and chronic renal disease.
  • Treatment according to the method treats or prevents chronic cardiac and vascular pathologies that involve endothelial dysfunction.
  • the method prevents or treats coronary endothelial dysfunction (CED).
  • CED coronary endothelial dysfunction
  • the subject is diagnosed as having or is suspected of CED and, as a result, is identified as in need to treatment to prevent or reduce the risk of experiencing coronary conditions or CAD.
  • CAD coronary endothelial dysfunction
  • localization peptide of the present invention is for use in a method where it is administered one or more times over defined period of time.
  • short term administration of the inhibitor is appropriate.
  • targeted delivery of the inhibitor of TERT nuclear localization is preferable to limit systemic exposure upon administration to the subject.
  • Effective amounts of therapeutic agents can depend on various factors, such as the activities of the particular agents used, the frequency of administration, the duration of treatment, the severity of the condition being treated, and the condition and prior medical history of the mammal being treated.
  • a dose that is lower than an effective dose can initially be administered to a mammal, and the dose can then be gradually increased over time until the desired effect is achieved.
  • Also disclosed herein is a method of modulating endothelial function, where the method comprises or consist essentially of administering to a subject an effective amount of an inhibitor of TERT mitochondrial translocation, whereby administration of the inhibitor of TERT mitochondrial translocation modulates endothelial function in the subject.
  • the frequency and duration of administration can be any frequency or duration that improves a symptom of, for example, CED without being toxic.
  • an agent can be administered once or twice a day, once every other day, once or twice a week, or as needed.
  • the frequency of administration can remain constant or can be variable during the duration of treatment.
  • An effective duration of treatment can vary from several weeks to several months or years.
  • an effective duration of treatment can be six months, five years, or a lifetime.
  • a course of treatment can include rest periods. Multiple factors can influence the actual effective frequency and duration of treatment. For example, the activities of the particular therapeutic agents used, the severity of the condition being treated, the doses administered, and the condition and prior medical history of the mammal being treated can affect the effective frequency and duration of treatment.
  • compositions provided herein can be administered primarily orally, intravenously, parenterally, sublingually or transdermally.
  • the corresponding drug preparation is preferably produced in liquid or solid form. Solutions are suitable for this purpose, especially for preparation of drops, injections or aerosol sprays, in addition to suspensions, emulsions, syrups, tablets, film tablets, coated tablets, capsules, pellets, powders, pastilles, implants, suppositories, creams, gels, salves, plasters or other transdermal systems.
  • telomere reactivation of the telomerase enzyme in certain cell types may also be an important event in oncogenic transformation, given the role of telomerase in cellular immortalization and proliferation.
  • the mechanisms that underlie the beneficial effects of telomerase reactivation in the prevention and amelioration of cardiac and vascular diseases have to this point been unclear.
  • mitochondrial-associated telomerase and not nuclear telomerase is the cause of cardiovascular protection associated with telomerase activity.
  • novel peptide therapeutics that are capable of specifically altering telomerase localization.
  • telomere localization increases cytoplasmic (including mitochondrial) telomerase localization and more importantly, activity.
  • these novel therapeutics could be combined with traditional and targeted cancer therapies to minimize toxicity to the vasculature and heart.
  • modulation of telomerase localization may be the basis of an entirely new way to treat microvessel, vascular and cardiac disease, including both chronic and acute conditions.
  • Example 1 Use of Peptides to Modulate Telomerase Localization: Implications for Vascular Function & Disease
  • Decoy peptide development Decoy peptides encompassing the telomerase NLS were designed based on the characterization of the telomerase NLS previously performed ( Chung et al., Cell Sci, 2012. 125(Pt 11): p. 2684-97 ). Peptide sequences were designed based on the amino acid sequence of human telomerase (hTERT; UniProt 014746).
  • Peptides Synthesis and Handling Peptide synthesis was conducted by GeneMed Synthesis (San Antonio, TX). All peptide sequences were verified by mass spectrometry, and were only used at a purity of greater than 95%. Lyophilized peptides were stored at -20 degrees Celsius. Given the charge properties of the peptides used in these studies, phosphate buffered saline (PBS) was selected as the solvent of choice to dissolve all peptides used. Following dissolution of peptides in PBS, peptide aliquots (to minimize freeze/thaw cycles) were stored at - 80 degrees Celsius.
  • PBS phosphate buffered saline
  • Microvessels were dissected from surgical discard tissues, predominantly consisting of adipose. Only vessels with a diameter of less than 300 micrometers were selected for further study. All microvessels were obtained from discarded surgical tissues, in accordance with an Institutional Review Board approved protocols (PRO00000114, PRO00010828, PRO00001094) at the Medical College of Wisconsin, Milwaukee, WI.
  • vessels were incubated overnight in complete endothelial cell media, supplemented with 5% fetal bovine serum (Lonza) with or without peptides as described. Following overnight incubation, peptides were washed out and vessels were cannulated and transferred to physiological salt solution.
  • a video microscopy setup enabled monitoring of vessels in real time. Vessels were pre-constricted with endothelin-1 (ET-1) at a dose range of 0.1-1 nM. Only vessels capable of constricting at least 20% from baseline were included in the study. Flow-mediated dilation (FMD) and Ach-induced dilation were then evaluated, followed by evaluation of endothelium-independent dilation to papaverin. After establishing this baseline, vessels were pre-constricted again with ET-1 and dilator curves repeated in the presence of Angiotensin II (ANG II), as described below.
  • ET-1 endothelin-1
  • ANG II Angiotensin II
  • FMD was evaluated by adjusting the heights of two reservoirs in equal and opposite directions to generate flow by altering vessel central pressure. After each change in pressure gradient, vessel diameter was measured and assessed using video microscopy. Prior to measuring FMD, all vessels studied were pre-constricted using endothelin-1.
  • ANG II Challenge Baseline vessel parameters, including ability to dilate in response to FMD, as described above were assessed. Following assessment, vessels were treated with ANG II at a final concentration of 10 nM for 30 minutes before FMD and response to ACh was re-assessed.
  • NCI-H1299 cell line was used for the cell culture experiments described in this manuscript. Cells were cultured in RPMI (Invitrogen) supplemented with 10% fetal bovine serum (Sigma).
  • Treated H1299 cells were fractionated into a nuclear and non-nuclear component using the NE-PER Nuclear and Cytoplasmic Extraction reagent kit (Thermo Fisher).
  • ddPCR TRAP Assay Cell lysates from H1299 cells treated overnight with nucXTERT peptides were obtained and fractionated, in accordance with the protocol established in the ThermoFisher NE:Per kit, resulting in a nuclear and non-nuclear fraction. A modified, quantitative telomerase repeat amplification protocol (TRAP assay) was performed.
  • Protein lysates were prepared following fractionation of H1299 cells into the nuclear and non-nuclear compartment, as described above. Following fractionation, protein within each sample was quantified using a BCA assay. 30 ⁇ g of protein was obtained from each fraction. Lysates were boiled and denatured. Samples, complete with loading dye were loaded into a 4-12% Bis-Tris gel. A current of 110V was applied for 75 minutes to separate proteins by size. Proteins were then transferred to a PVDF membrane (BioRad) for 2 hours at 100 V, over ice and with cooling.
  • membranes were blocked with 10% powdered blocking reagent (BioRad) dissolved in Tween-20 Tris-Buffered Saline (TBST) for 2 hours at room temperature. Following blocking, membranes were incubated with primary antibody (anti-hTERT (rabbit), Rockland, 1:500; anti-GAPDH (rabbit), Cell Signaling Technology, 1:1,000; anti-Histone H3, Cell Signaling Technology, 1:1,000) dissolved in 5% blocking agent TBST overnight at 4 degrees Celsius. Following overnight incubation, membranes were washed thoroughly with TBST and incubated with anti-rabbit antibody (Cell Signaling Technologies) at a 1:5000 dilution for 2 hours. Following thorough washing, membranes were incubated with Femto detection solution (hTERT; Histone H3) or BioRad ECL solution (GAPDH). Membranes were then imaged using an ECL detection system (BioRad).
  • nucXTERT Inhibitor is Effectively Taken Up by Living Tissues:
  • One of the first hurdles that required consideration when evaluating the ability of novel peptides to alter telomerase localization is their ability to be internalized by living tissues.
  • nucXTERT was labeled with 5-carboxyfluorescein (5-FAM).
  • 5-FAM 5-carboxyfluorescein
  • Isolated human microvessels incubated with the 5-FAM labeled peptide were analyzed by microscopy. Robust signal is present in vessels pulsed with the peptide, while vessels not treated with peptide have no signal.
  • in vitro experiments using human non-small cell lung cancer (H1299) cells confirm that labeled peptide effectively traffics into the cell.
  • the peptide is detectable in a perinuclear pattern ( FIG. 2 ). Since peptide is taken up by vessels, it was possible to study the effect of peptide treatment on vessel physiology, using human microvessels as described in the methods. Table 2 details the patient characteristics from whom microvessels were isolated for the remainder of the experiments conducted in this chapter. Table 2.
  • nucXTERT Inhibitor Alters Telomerase Localization: Telomerase activity assays as well as western blotting, depicted in FIGS. 3A-3B , reveal that H1299 cells pulsed with nucXTERT peptide have attenuated nuclear levels of telomerase. This is reflected in decreased telomerase activity, as measured by TRAP assay ( FIG. 3B ). Furthermore, treatment with nucXTERT increases accumulation of telomerase within the non-nuclear compartment.
  • nucXTERT Protects Human Microvessels from Stressors: Isolated human microvessels were pretreated with nucXTERT and challenged with angiotensin II (ANG II), a potent vasoconstrictor and vascular stressor involved in several disease pathologies (obesity, hypertension, renal failure, CAD to name a few). Vasodilation was evoked using increased intralumuinal flow (flow mediated dilation or "FMD”) or the endothelium-dependent agonist acetylcholine (ACh). Smooth muscle-dependent and endothelial cell-independent dilation was tested using papaverin.
  • FMD flow mediated dilation
  • ACh endothelium-dependent agonist acetylcholine
  • Treatment of microvessels with ANG II results in significantly diminished vasodilator responses to both acetylcholine and flow as measured by the percentage of maximum diameter.
  • Treatment of microvessels with BIBR1532, a known specific inhibitor of global telomerase activity effectively eliminates vasodilation in response to acetylcholine ( FIG. 4A , upper right), although vessels continue to dilate in response to flow stimulus ( FIG. 4B , upper right).
  • nucXTERT vasodilation in response to either ACh or flow stimuli is not impacted by ANG II treatment.
  • nucXTERT and BIBR1532 effectively abrogates the vasodilator protective effect of nucXTERT, suggesting that catalytic telomerase activity is required in order for nucXTERT to preserve baseline vasodilation in response to ANG II challenge.
  • nucXTERT and mitoXTERT peptides antagonize the adverse cardiac effects of angiotensin II (ANG II), which causes significant cardiac and vascular damage and is associated with hypertension and many other CV disease states.
  • ANG II angiotensin II
  • nucXTERT Modified Peptides Differentially Protect Vasculature It was not previously known or demonstrated that global inhibition of TERT activity increases sensitivity to stress induced endothelial dysfunction and has negative effects on cardiovascular outcomes, but specific inhibition of nuclear TERT localization and nuclear activity has protective effects on vasculature by maintaining mitochondrial TERT function. As described in this section, it was discovered that treatment of isolated human vessels with TERT peptide inhibitors attenuated vessel responses to stressors including ANG II in a manner that is suggestive that the peptide inhibitor may protect the vasculature from damage resulting from a number of chronic pathologies, oxidative stressors and chemotherapies associated with vascular and cardiac toxicities.
  • nucXTERT is a synthetic peptide homologous to one of the nuclear localization signals present in telomerase.
  • the serine residue at position 227 can be phosphorylated to initiate nuclear translocation of the protein.
  • nucXTERT -A does not protect vessels from attenuation of vasodilator capacity in response to AngII challenge with either flow or acetylcholine (ACh) dilation stimuli ( FIG. 5 ).
  • Vessels incubated with the A peptide at a concentration of 10 ⁇ M overnight had a mean diameter of 142 ⁇ m ⁇ 38.
  • Baseline vessel constriction was similar between both A and E peptide treated vessels, with A treated vessels constricting to an average of 53 ⁇ 12% of their maximum diameter after 10 minutes of ET-1 treatment, while E peptide treated vessels constricted to an average of 48 ⁇ 18% of their maximum diameter after 10 minutes of ET-1 treatment.
  • a peptide treated vessels dilated to a diameter of 82 ⁇ m ⁇ 11 at a 100 cm flow gradient.
  • E peptide treated vessels dilated to an average diameter of 136 ⁇ m ⁇ 51 at 100 cm of flow gradient, following ANG II treatment ( FIGS. 5A and 5B , right hand panels).
  • nucXTERT-E When A peptide treated vessels were exposed to ANG II and stimulated with ACh, vessels dilated to an average diameter of 128 ⁇ m ⁇ 33. E peptide treated vessels treated with ANG II and stimulated with ACh dilated to an average diameter of 131 ⁇ m ⁇ 24.
  • the phosphomimetic nucXTERT referred to herein as nucXTERT-E prevents ANG II-induced endothelial dysfunction in isolated microvessels under both flow and ACh stimulus conditions, at a level which is indistinguishable from treatment with the wild type sequence.
  • nucXTERT Inhibitor Restores Healthy Vasodilatory Mechanisms in Diseased Tissues Diseased microvessels exhibiting vascular dysfunction were obtained from adipose tissue of donors with clinically confirmed coronary artery disease. At baseline, these vessels respond to vasodilatory stimuli through the use of H2O2 as a signaling mechanism to enable dilation. Treatment of vessels with PEG-Catalase, a scavenger of H2O2 effectively attenuates vasodilation. However, treatment with L-NAME, an inhibitor of nitric oxide synthase does not impact the ability of diseased vessels to dilate.
  • vessels from healthy donors exhibit the opposite trend; treatment with PEG-Catalase does not impact dilation potential, while treatment with L-NAME significantly attenuates the ability of the vessels flow stimuli.
  • H 2 O 2 represents the dominant vasodilator.
  • NO is restored as the main mechanism of FMD.
  • treatment with PEG-Catalase no longer inhibits dilation responses ( FIG. 6 , top panels).
  • treatment with mitoXTERT causes healthy vessels to undergo the converse change, from NO-mediated dilation to H 2 O 2 -dependent dilation ( FIG. 6 , bottom panels).
  • nucXTERT with S->E substituton was PEGylated at the C-terminus to increase bio stability and cell permeability.
  • Effective doses from 10 ⁇ M to 1 nM were tested ( FIGS. 7A-7C ).
  • PEGylated peptide could be titrated down to 1nM with vascular protective effects.
  • the mechanism of FMD did not alter (L-NAME inhibitable, FIG. 7B ) but protected against ANG II induced endothelial dysfunction ( FIG. 7C ).
  • Peptide biodistribution in vivo To assay peptide biodistribution in vivo, pegylated peptide (50 nM) was radiolabeled with Technetium (Tc 99m) for radiotracing. Technetium- labeled peptide (0.77 nM) was injected into the tail vein of normal C57 mice.
  • Tc 99m Technetium- labeled peptide
  • FIGS. 8A-8K mice were euthanized at 2, 4, and 8 hours after injection and remaining radioactivity determined in individual organs. Signals were normalized to blood. In every major organ significant increase of signal was observed up to 8 hours after injection, suggesting the peptide was not degraded at this time.
  • FIG. 8A-8K mice were euthanized at 2, 4, and 8 hours after injection and remaining radioactivity determined in individual organs. Signals were normalized to blood. In every major organ significant increase of signal was observed up to 8 hours after injection, suggesting the peptide was not degraded at this time.
  • mice were injected subcutaneously (subQ) with radiolabeled peptide (0.77 nM) and remaining activity was determined in blood after 24 hours and 48 hours. While signal was significantly lower in subQ mice as compared to IV injection, increased signal relative to background was observed after 24 hours but not 48 hours.
  • radiolabeled peptide (0.77 nM)
  • the peptide is distributed in the circulation for at least 24 hours after subQ injection.
  • our data demonstrate that the peptide crosses the blood brain barrier -- an advantageous property of the peptides provided herein that could prove important to the treatment of cerebral vascular dysfunction or neurological disorders.
  • Peptides having bioactivity in the CNS in vivo open up a realm of possible therapeutic options for neurologic diseases cerebral vascular disorders.
  • telomere inhibitor nuclear telomerase inhibitor
  • nucXTERT treatment of isolated human microvessels dissected from adipose tissue of healthy patients are protected from vascular stressors by nucXTERT treatment ( FIG. 4 ).
  • Use of a modified nucXTERT peptide containing a glutamic acid for serine substitution at position 227 of the endogenous NLS also reveals striking vasoprotective effects.
  • substitution of serine with alanine at the same position abrogates the effectiveness of nucXTERT, suggesting that this is a critical residue for the function of this peptide, and that our synthetic modification of the peptide may enhance function ( FIG. 5 ).
  • nucXTERT is capable of altering the mechanisms responsible for vasodilation in tissues from patients with coronary artery disease.
  • nucXTERT restores vascular dilation to primarily nitric oxide (NO)-dependent mechanisms, as seen in healthy microvessels.
  • mitoXTERT which is a peptide corresponding to the mitochondrial localization sequence (MLS) of telomerase, causes healthy tissues that are normally dependent on NO mediated dilation to become dependent on hydrogen peroxide to dilate in response to flow ( FIG. 6 ).
  • telomerase activity has a protective effect on the ability of the vasculature to resist stressors. This point has also been dramatically proved in vivo in models of cardiac injury and myocardial infarction, where overexpression of telomerase using AAV-vectors leads to significantly better recovery and lower mortality post-MI in a rodent model (Bär et al, 2014). Given data suggesting that telomerase can modulate the mechanism of vasodilation, the question or where the enzyme is acting is highly salient. We have demonstrated here that using decoy peptides, the telomerase pool can be effectively manipulated.
  • telomerase shifting telomerase to a predominantly non-nuclear localization also results in vasoprotection. Intriguingly, this vasoprotective effect is abolished when the catalytic activity of telomerase is inhibited. This suggests that the vasoprotective phenotype is dependent on telomerase activity, and that the inhibitor is specifically manipulating telomerase.
  • the development of several different peptides further reveals the specificity of action of nucXTERT; mutation at one residue effectively prevents the peptide from protecting the vasculature. This strongly suggests that this is a highly specific therapeutic; the protective effect observed ex vivo is not due to treatment of tissues with peptide non-specifically- rather, this particular peptide is specific.
  • telomerase is capable of restoring normal vasodilator potential and normal mechanisms of vasodilation (NO mediated versus hydrogen peroxide) in freshly isolated human microvessels from patients with coronary artery disease.
  • This immediately suggests the utility of this approach and these therapeutics in correcting vascular dysfunction associated with this disease state in this patient population.
  • this approach in treating other cardiac and vascular diseases that involve microvessel dysfunction, including but not limited to CAD, Prinzmetal's angina and others.
  • telomerase inhibitors that are in clinical trials have demonstrated anti-tumor efficacy.
  • These therapies may increase endothelial dysfunction and increase risks such as thrombosis. This is particularly troubling given the length of time that patients may need to take anti-telomerase regimens in order to see activity against tumors.
  • telomere elongation that is required for tumor cell proliferation
  • nucXTERT peptides could help to address these toxicities by shifting the nuclear pool of telomerase to protect endothelial cell health.
  • telomerase does in fact localize not just to the cytoplasmic pool, but more specifically to the mitochondrial compartment following treatment with nucXTERT.
  • experiments to confirm altered telomerase localization after treatment with the phosphomimetic peptide (nucXTERT-E) as well as following treatment with the phosphorylation-deficient peptide (nucXTERT-A) should be conducted. These experiments would involve fractionation of treated cells and potentially vessels with subsequent Western blotting and TRAP assay experiments to validate both increase protein levels and activity within the mitochondrial compartment.
  • Example 2 NLS Peptide Inhibitor May Decrease Lung Tumor Cell Migration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Claims (14)

  1. Peptide isolé comprenant une séquence d'acide aminé telle que définie par : SEQ ID NO : 2 ou SEQ ID NO : 4, le peptide isolé étant capable d'empêcher la translocation nucléaire de TERT.
  2. Peptide isolé selon la revendication 1, tel qu'indiqué par SEQ ID NO:2.
  3. Peptide isolé selon l'une quelconque des revendications précédentes, dans lequel :
    (a) le peptide est perméable à BBB ;
    (b) le peptide est PEGylé, préférablement dans lequel le peptide PEGylé comprend la séquence indiquée dans SEQ ID NO : 4 ;
    (c) le peptide comprend en outre une ou plusieurs modifications choisies parmi la PEGylation, la myristoylation, la glycosylation, l'acétylation, la phosphorylation et l'ajout d'un lieur ou d'un espaceur ; ou
    (d) le peptide est un peptide inverso ou rétro-inverso.
  4. Polynucléotide isolé comprenant une séquence d'acide nucléique codant pour un peptide comprenant le peptide isolé de l'une quelconque des revendications précédentes.
  5. Procédé in vitro de prévention de la translocation nucléaire d'une enzyme télomérase dans une cellule humaine, le procédé comprenant la mise en contact de la cellule humaine avec un inhibiteur de la translocation nucléaire de TERT comprenant SEQ ID NO : 2 ou SEQ ID NO : 4.
  6. Inhibiteur peptidique de la translocation nucléaire de TERT comprenant SEQ ID NO : 2 ou SEQ ID NO : 4 pour une utilisation dans un procédé de prévention de la translocation nucléaire d'une enzyme télomérase dans une cellule humaine, le procédé comprenant la mise en contact de la cellule humaine avec l'inhibiteur de translocation nucléaire de TERT.
  7. Inhibiteur peptidique de la translocation nucléaire de TERT comprenant SEQ ID NO : 2 ou SEQ ID NO : 4 pour une utilisation dans un procédé selon la revendication 6, dans lequel l'administration est une administration parentérale.
  8. Inhibiteur peptidique de la translocation nucléaire de TERT comprenant SEQ ID NO : 2 ou SEQ ID NO : 4 pour une utilisation dans un procédé de réduction des effets cardiaques indésirables chez un sujet, le procédé comprenant l'administration d'une quantité thérapeutiquement efficace d'un inhibiteur de la translocation nucléaire de TERT à un sujet, dans lequel l'administration du peptide synthétique réduit l'apparition d'effets cardiaques indésirables chez le sujet.
  9. Inhibiteur peptidique de la translocation nucléaire de TERT comprenant SEQ ID NO : 2 ou SEQ ID NO : 4 pour une utilisation selon la revendication 8, dans lequel :
    (a) les effets cardiaques indésirables sont une cardiotoxicité associée à l'administration d'un agent chimiothérapeutique au sujet ;
    (b) le sujet recevra ou reçoit un agent chimiothérapeutique ; ou
    (c) l'administration est une administration parentérale.
  10. Inhibiteur de la translocation nucléaire de TERT pour une utilisation selon la revendication 8 ou 9, dans lequel l'inhibiteur de la translocation nucléaire de TERT est un peptide.
  11. Peptide isolé comprenant SEQ ID NO : 2 ou SEQ ID NO : 4 pour une utilisation dans un procédé de traitement d'une maladie hyperproliférative chez un sujet, le procédé comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un peptide isolé au sujet ; le peptide isolé étant capable d'empêcher la translocation nucléaire de TERT, traitant ainsi la maladie hyperproliférative.
  12. Peptide isolé comprenant SEQ ID NO : 2 ou SEQ ID NO. 4 pour une utilisation selon la revendication 11, dans lequel :
    (a) la maladie hyperproliférative est le cancer ; et
    (b) le peptide est PEGylé, plus préférablement dans lequel le peptide PEGylé comprend la séquence indiquée dans SEQ ID NO : 4.
  13. Inhibiteur peptidique de la translocation nucléaire de TERT comprenant SEQ ID NO : 2 ou SEQ ID NO : 4 pour une utilisation dans un procédé de réduction du stress oxydatif, le procédé comprenant l'administration à un sujet d'une quantité efficace de l'inhibiteur de la translocation nucléaire de TERT.
  14. Inhibiteur peptidique de la translocation nucléaire de TERT pour une utilisation selon la revendication 13, dans lequel l'inhibiteur de la translocation nucléaire de TERT est un peptide, dans lequel le peptide est un peptide inverso ou rétro-inverso.
EP16762938.5A 2015-08-28 2016-08-26 Inhibiteurs peptidiques de translocation de la télomérase et leurs utilisations thérapeutiques Active EP3341389B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562211524P 2015-08-28 2015-08-28
PCT/US2016/049053 WO2017040309A1 (fr) 2015-08-28 2016-08-26 Inhibiteurs peptidiques de translocation de la télomérase et leurs utilisations thérapeutiques

Publications (2)

Publication Number Publication Date
EP3341389A1 EP3341389A1 (fr) 2018-07-04
EP3341389B1 true EP3341389B1 (fr) 2021-10-06

Family

ID=56883870

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16762938.5A Active EP3341389B1 (fr) 2015-08-28 2016-08-26 Inhibiteurs peptidiques de translocation de la télomérase et leurs utilisations thérapeutiques

Country Status (7)

Country Link
US (1) US10858397B2 (fr)
EP (1) EP3341389B1 (fr)
JP (1) JP2018532381A (fr)
CN (1) CN108350033A (fr)
AU (1) AU2016316774A1 (fr)
CA (1) CA2996951C (fr)
WO (1) WO2017040309A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230124973A1 (en) * 2017-12-15 2023-04-20 Kenkichi Masutomi Screening method for telomerase reverse transcriptase (tert) phosphorylation inhibitors
CN110004180B (zh) * 2019-04-16 2023-08-18 上海海洋大学 一种由功能肽a25修饰的基因载体及其制备方法和应用
WO2024178250A1 (fr) * 2023-02-22 2024-08-29 Radella Pharmaceuticals Llc Inhibiteurs de l'interaction ptp1b/nck1 et leurs procédés de fabrication et d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100003229A1 (en) * 2008-06-19 2010-01-07 Santos Janine H Nuclear telomerase reverse transcriptase variant
US20100074925A1 (en) * 2006-09-21 2010-03-25 Vaxil Biotherapeutics Ltd Antigen specific multi epitope vaccines
WO2014012683A1 (fr) * 2012-07-20 2014-01-23 Kael-Gemvax Co.,Ltd. Peptides anti-inflammatoires et composition en contenant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1994942A1 (fr) * 2007-05-25 2008-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions pharmaceutiques comprenant de la télomérase et leurs utilisations
CN110092817B (zh) * 2012-09-19 2023-04-18 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074925A1 (en) * 2006-09-21 2010-03-25 Vaxil Biotherapeutics Ltd Antigen specific multi epitope vaccines
US20100003229A1 (en) * 2008-06-19 2010-01-07 Santos Janine H Nuclear telomerase reverse transcriptase variant
WO2014012683A1 (fr) * 2012-07-20 2014-01-23 Kael-Gemvax Co.,Ltd. Peptides anti-inflammatoires et composition en contenant

Also Published As

Publication number Publication date
EP3341389A1 (fr) 2018-07-04
CA2996951A1 (fr) 2017-03-09
CN108350033A (zh) 2018-07-31
US10858397B2 (en) 2020-12-08
CA2996951C (fr) 2024-05-07
AU2016316774A1 (en) 2018-03-22
US20180251491A1 (en) 2018-09-06
WO2017040309A1 (fr) 2017-03-09
JP2018532381A (ja) 2018-11-08

Similar Documents

Publication Publication Date Title
Snyder et al. Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids invivo
US20220056088A1 (en) Peptide directed protein knockdown
KR102714599B1 (ko) Npra 작용제, 조성물 및 이의 용도
US10273279B2 (en) Protease activated receptor-1 (PAR1) derived cytoprotective polypeptides and related methods
EP3341389B1 (fr) Inhibiteurs peptidiques de translocation de la télomérase et leurs utilisations thérapeutiques
JP2013518119A (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
US20210046148A1 (en) Methods for Increasing the Selective Efficacy of Gene Therapy Using CAR Peptide and Heparan-Sulfate Mediated Macropinocytosis
CN114026114A (zh) 用于治疗再灌注损伤的bnip3肽
Kwiatkowska et al. Novel Insights into Structure–Activity Relationships of N‐Terminally Modified PACE4 Inhibitors
US10335449B2 (en) Rho associated kinase (ROCK) inhibitors and their use in treating disease
AU2019386379A1 (en) DPEP-1 binding agents and methods of use
US20210371478A1 (en) Generation of brain and spinal cord neurons, cardiac myocytes, and hepatocytes using reg peptides, peptidomimetics, small molecules and stimulatory antibodies to reg receptor
US9815867B2 (en) Peptide for inhibiting vascular endothelial growth factor receptor
ES2873956T3 (es) Péptidos y métodos de uso
US9408888B2 (en) High affinity bivalent helically constrained peptide against cancer
US20140005119A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
WO2010117055A1 (fr) Polypeptide ayant une activité inhibitrice sélective contre la protéine kinase cα ou η
WO2005090570A9 (fr) Compositions therapeutiques et methodes de traitement de maladies impliquant l'angiogenese
CN113195704A (zh) 用于治疗癌症的肽治疗剂及其用途
EP2060581A1 (fr) Protéines de squelette pour aptamères de peptides recombinants
KR20160042214A (ko) Ｐｅａ15 융합단백질을 포함하는 뇌허혈 치료용 약학 조성물

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180309

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

PUAG Search results despatched under rule 164(2) epc together with communication from examining division

Free format text: ORIGINAL CODE: 0009017

17Q First examination report despatched

Effective date: 20191113

B565 Issuance of search results under rule 164(2) epc

Effective date: 20191113

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 49/00 20060101ALI20191108BHEP

Ipc: C07K 7/08 20060101AFI20191108BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210618

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1436161

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211015

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016064647

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20211006

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1436161

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211006

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220106

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220206

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220207

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220106

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220107

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016064647

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20220707

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220826

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220831

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20220831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20160826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211006

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240717

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240718

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240726

Year of fee payment: 9